AbbVie's Vraylar, carrying $4B sales target, wins FDA label expansion in depression

AbbVie's Vraylar, carrying $4B sales target, wins FDA label expansion in depression

Submitted by admin on December 19, 2022 - 10:05pm
Source: 
Fierce Pharma
News Tags: 
AbbVie
Vraylar
depression
FDA
Headline: 
AbbVie's Vraylar, carrying $4B sales target, wins FDA label expansion in depression
snippet: 

AbbVie's Vraylar, already a blockbuster, on Monday grabbed a coveted label expansion treat depression alongside an antidepressant therapy.

Do Not Allow Advertisers to Use My Personal information